Susceptibility of Type I Interferon Receptor Knock-Out Mice to Heartland Bandavirus (HRTV) Infection and Efficacy of Favipiravir and Ribavirin in the Treatment of the Mice Infected with HRTV.
Heartland bandavirus
animal model
favipiravir
ribavirin
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
28 07 2022
28 07 2022
Historique:
received:
24
06
2022
revised:
20
07
2022
accepted:
27
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Heartland bandavirus (HRTV) is an emerging tick-borne virus that is distributed in the United States and that causes febrile illness with thrombocytopenia and leukocytopenia. It is genetically close to Dabie bandavirus, which is well known as severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV). The mortality rate of human HRTV infection is approximately 10%; however, neither approved anti-HRTV agents nor vaccines exist. An appropriate animal model should be developed to evaluate the efficacy of antiviral agents and vaccines against HRTV. The susceptibility of IFNAR
Identifiants
pubmed: 36016290
pii: v14081668
doi: 10.3390/v14081668
pmc: PMC9416051
pii:
doi:
Substances chimiques
Amides
0
Pyrazines
0
Solvents
0
Receptor, Interferon alpha-beta
156986-95-7
Ribavirin
49717AWG6K
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Infect Dis. 2014 Mar;209(6):816-27
pubmed: 24231186
Viruses. 2021 May 11;13(5):
pubmed: 34064604
Arch Virol. 2020 Dec;165(12):3023-3072
pubmed: 32888050
J Virol. 2014 Feb;88(3):1781-6
pubmed: 24257618
Viruses. 2018 Sep 14;10(9):
pubmed: 30223439
Am J Trop Med Hyg. 2017 Oct;97(4):992-996
pubmed: 28820686
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
Clin Exp Vaccine Res. 2018 Jan;7(1):43-50
pubmed: 29399579
Adv Exp Med Biol. 2017;972:87-101
pubmed: 27722960
PLoS One. 2018 Oct 26;13(10):e0206416
pubmed: 30365543
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):929-939
pubmed: 33188497
MMWR Morb Mortal Wkly Rep. 2014 Mar 28;63(12):270-1
pubmed: 24670929
Emerg Infect Dis. 2013 Nov;19(11):1892-4
pubmed: 24206586
Am J Trop Med Hyg. 2013 Sep;89(3):445-452
pubmed: 23878186
N Engl J Med. 2011 Apr 21;364(16):1523-32
pubmed: 21410387
J Virol. 2022 Apr 13;96(7):e0004922
pubmed: 35319224
PLoS Pathog. 2011 Nov;7(11):e1002369
pubmed: 22114553
Jpn J Infect Dis. 2014;67(6):423-7
pubmed: 25410555
Clin Infect Dis. 2017 Feb 15;64(4):510-512
pubmed: 27927857
J Biol Chem. 2019 Jun 14;294(24):9503-9517
pubmed: 31040183
Curr Opin Immunol. 2011 Aug;23(4):481-6
pubmed: 21840185
Emerg Infect Dis. 2016 Dec;22(12):2070-2077
pubmed: 27869591
Emerg Infect Dis. 2019 May;25(5):1029-1031
pubmed: 31002059
Front Microbiol. 2017 Jan 30;8:104
pubmed: 28194148
Virology. 2017 Nov;511:175-183
pubmed: 28865344
Emerg Infect Dis. 2019 Feb;25(2):358-360
pubmed: 30511916
Emerg Microbes Infect. 2020 Dec;9(1):148-151
pubmed: 31918622
Antiviral Res. 2013 Nov;100(2):446-54
pubmed: 24084488
N Engl J Med. 2012 Aug 30;367(9):834-41
pubmed: 22931317
mSphere. 2016 Jan 06;1(1):
pubmed: 27303697
Curr Opin Virol. 2014 Oct;8:10-5
pubmed: 24846716
Front Immunol. 2018 Sep 11;9:2061
pubmed: 30254639
J Virol. 2018 Jun 13;92(13):
pubmed: 29643242
Respir Res. 2005 Nov 11;6:135
pubmed: 16283933
Emerg Infect Dis. 2018 May;24(5):893-897
pubmed: 29664369
Virology. 2015 Aug;482:19-27
pubmed: 25817401
Clin Infect Dis. 2014 Sep 15;59(6):845-50
pubmed: 24917656